^BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) — Novotech, the global clinical
Contract research organization (Clinical Research Organization, CRO) with comprehensive
Service that works with biotech companies to develop
to accelerate advanced and novel therapeutics at every stage,
today released two industry-leading reports on the clinical trial landscape
Candidiasis and rheumatoid arthritis published.
Of particular importance is that the reports also include a SWOT analysis
included, which serves as a basis for decision-making for the strategic
Drug development serves and ultimately the chances of successful and
effective treatments increased.
Novotech’s team of research analysts provides these expert reports on a monthly basis
available completely free of charge. These reports provide up-to-date insights into the
global activity of clinical trials and show in which regions the
highest study volumes have been recorded and what factors are behind them
Trends stand. They address the hurdles that biotech companies face
certain therapeutic areas and discuss future ones
Therapy paths and investment trends.
The report Candidiasis – Global Clinical Trial Landscape
(https://bit.ly/42eyrb5) (Candidiasis – Global Clinical Trial Landscape)
investigates the question of why this fungal infection, which primarily affects the oral cavity and
which affects the reproductive organs, has become an important global problem
is, especially in people with weakened immune systems. The report
also focuses on the epidemiology, the therapeutic
Challenges and evolving clinical trial data trends,
provides healthcare professionals and researchers with extremely valuable insights
offer.
Since 2018, over 200 clinical trials for candidiasis have been initiated worldwide,
with the APAC region leading the way with almost 60% of studies, most of them
in mainland China. This is followed by Europe (23%), North America (10%) and the rest of the
World (7%).
This global report shows that candidiasis in different regions
occurs at different frequencies, which is due to the interaction of factors such as
Geography, health infrastructure and demographics. The
Report also highlights the global dominance of Candida albicans
Invasive and non-invasive candidiasis prevalence and the challenges
of treatment arising from drug-resistant strains.
Key findings from the report include:
* In the APAC region, the focus remains on Phase I studies
Europe for Phase I, II and III studies and in North America for Phase III studies
Studies.
* APAC has a robust 20% annual clinical growth rate
studies, surpassing other global regions.
* Recruitment rates differ significantly between APAC, Europe
and the USA.
*Notable breakthroughs in antifungals include the
Approvals for Brexafemme, Vivjoa and Rezzayo, which are used for the treatment of
Candidiasis to be optimistic.
* On the venture capital front, the US and China are leading the way and underlining
thus the common interest in promoting treatment solutions
against candidiasis through solid financing, especially in series B
and C.
The report also provides a detailed insight into ongoing research
potential antifungal vaccines.
Download the report here (https://bit.ly/42eyrb5)
The Rheumatoid Arthritis (RA)-Global Clinical Trial Landscape report
(https://bit.ly/3OmRlqo) (Rheumatoid Arthritis (RA) – Global Clinical
Study landscape) examines the global prevalence and identifies the
Key factors driving this disease. RA, a stubborn one
inflammatory disease of the joints, affects people aged 60 to 70
years, with women being disproportionately affected.
The report highlights the crucial role of early diagnosis
and treatment with conventional synthetic disease modifying agents
Antirheumatic drugs and the effectiveness of biological or targeted ones
synthetic disease-modifying antirheumatic drugs. Really important
is that also the latest advances in molecular medicine, epigenetic
Drugs, microRNAs, gene editing technologies and the role of the microbiome
be treated.
Since 2018, over 1,100 RA clinical trials have been initiated worldwide
the APAC region leads with 60%, followed by Europe with 21% and
North America at 13%.
The report also notes that there is promising progress in
There are new RA therapeutics: more than 80 drugs are available
preclinical stage, 52 in phase I studies and 4 in combined phase I/II studies
Studies. In addition, 61 drugs are in phase II and 19 in
Phase III, with 9 approved and 82 already on the market.
Overall, this report provides important insights into the global landscape of the
clinical trials and describes ongoing developments in RA
Research. Additionally, SWOT analysis provides a rare perspective for
the strategic planning of drug development.
Key findings from the report include:
* In 2020, RA affected 17.6 million people worldwide, leading to
38,300 deaths.
* In the APAC region, China has the most cases with 4.7 million
In India there are 2.67 million, in Europe the United Kingdom stands out
with 458,000 cases, and the United States is in North America
with 1,440,000 cases ahead.
* Study phases vary worldwide, with the APAC region
Phase I dominates, in Europe a balance between all phases
and in North America the focus is on Phase I.
* In recent years, China has been a leader in venture capital investment,
closely followed by the USA.
* The distribution of funds across the individual financing rounds shows that
the focus is on later phases, particularly Series C, which
on greater investor confidence and higher financing amounts
for mature companies.
* Most investments were in early-stage research,
particularly on the preclinical phase, which shows that the focus is on
groundbreaking discoveries and innovative treatments.
This comprehensive resource helps healthcare professionals, researchers and
Organizations navigating the complex landscape of clinical trials
to find your way around.
Download the report here (https://bit.ly/3OmRlqo)
About Novotech Novotech-CRO.com (https://novotech-cro.com/reports/gall-bladder-
cancer-global-clinical-trial-
landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT
&utm_term=DOWNLOAD REPORT&utm_content=GBC)
Founded in 1997, Novotech is a global clinical
Full-service contract research organization (CRO) focused on
Collaboration with biotech companies focused on development
of advanced and novel therapeutics at every stage.
Recognized for its industry-leading contributions, Novotech has numerous
Received prestigious awards including the CRO Leadership Award
2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023 and
since 2006 the Asia-Pacific Contract Research Organization Company of the Year
Award.
The company offers a full range of services including
Laboratories, Phase I facilities, drug development consulting and
regulatory expertise, and has experience with over 5,000 clinical
Projects, including phase I to IV clinical trials and
Bioequivalence studies. With a presence in 34 locations and a dedicated
With a team of more than 3,000 professionals worldwide, Novotech is a trusted one
strategic end-to-end partner of choice.
For more information or speak to an expert from our team
To speak, visit www.Novotech-CRO.com (http://www.novotech-cro.com/).
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/3fc9701b-b0f3-432e-bac0-
5c8bf0bf5070
https://www.globenewswire.com/NewsRoom/AttachmentNg/db8d6332-f46b-
4922-852d-2f2b1e4b77c0
°